Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: Bear Down who wrote (435)	12/11/1998 12:16:00 PM
From: Mr.Manners	Read Replies (1) \| Respond to of 645

To: yields (662 ) From: Street Walker Friday, Dec 11 1998 11:55AM ET Reply # of 685 AVIR - fda REJECTED ...requires more studies not on all wires. Support not until $15 market makers pushing it down. going to tank when people realize this over the weekend. S.W. Thursday December 10, 4:05 pm Eastern Time Company Press Release SOURCE: Aviron Aviron Meets With FDA Regarding FluMist(TM) License Applications Bridging Trial Based on Safety and Immunogenicity Initiated in Australia MOUNTAIN VIEW, Calif., Dec. 10 /PRNewswire/ -- Aviron (Nasdaq: AVIR - news) today reported on discussions in a recent meeting with the U.S. Food and Drug Administration Center for Biologics Evaluation and Research (CBER) regarding plans for submission of Aviron's license applications for its FluMist intranasal influenza vaccine. On August 31, Aviron reported that it had received notice from the FDA that its license applications were not accepted for filing due to lack of data on manufacturing, validation and stability. ''We had a productive meeting with the FDA, and received valuable input regarding our plans. We feel confident that we will be able to comply fully with the requirements of the agency,'' said J. Leighton Read, M.D., Aviron's chairman and chief executive officer. ''Aviron is moving forward to implement its action plan based on this meeting, with the goal of submitting our applications by the summer or fall of 1999.'' At the meeting, Aviron discussed its plans to complete requirements for submission. Requirements include data on manufacturing, validation and stability. In addition, Aviron will conduct a bridging study designed to evaluate clinical equivalence of vaccine blended and filled at Aviron's new Pennsylvania facility as compared to vaccine used in earlier clinical trials. This 225-person trial has been initiated in Australia in collaboration with CSL Limited, Aviron's Australian marketing partner for FluMist and a leading supplier of vaccines in the Southern Hemisphere. The study will be conducted by principal investigators Terry Nolan, MB, BS, Ph.D., FRACP, FAFPHM and Geoff Hogg, MB, BS, FRACP, FRCPA at the Royal Children's Hospital, Melbourne. Aviron will include safety and immunogenicity data from this clinical study in its licensing applications for the vaccine. Aviron is a biopharmaceutical company based in Mountain View, CA focused on prevention of disease. The company's goal is to develop products which offer cost-effective prevention of a wide range of infections that affect the general population. The majority of Aviron's products under development are live vaccines against viral infections. These include intranasal vaccines under development for respiratory infections and their complications -- influenza, parainfluenza (PIV-3), and respiratory syncytial virus (RSV), and injectable vaccines to prevent cytomegalovirus (CMV) and genital herpes (HSV-2). Aviron is also developing, in collaboration with SmithKline Beecham Biologicals, a subunit vaccine against Epstein-Barr Virus (EBV) infection, a major cause of infectious mononucleosis. This press release contains forward-looking statements. Actual results may differ materially from those suggested here. Factors that could cause actual results to differ include, but are not limited to, failure in a clinical trial, failure to demonstrate stability or to validate equipment or the manufacturing process. Risk factors also include the assessment by the FDA that the company's future license applications for its intranasal influenza vaccine are incomplete or inadequate to approve the product for marketing to one or more target populations. Additional information concerning factors that could cause such a difference is contained in Aviron's Annual Report on Form 10-K for the year ended December 31, 1997. To receive an index and copies of recent press releases, call Aviron's News-On-Call toll-free fax service, 800-758-5804, extension 114000. Additional information about the company can be located at aviron.com. SOURCE: Aviron